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Abstract
Bronchial asthma is an autoimmune disease, one of the most common and practically non-treatable by standard
methods. At present, the used drugs only maintain a state of temporary remission, simultaneously having a negative
effect on various organs and structures and causing side effects.
At the same time, the experts have ignored more than 50 years of successful experience of low-level laser therapy, the
results of hundreds of studies proving the effectiveness of the method in treating patients with all forms of bronchial
asthma. It is proved that therapeutic and periodic (2e4 per year) courses of low-level laser therapy can signiﬁcantly
decrease the frequency and severity of attacks, reduce or cancel the reception of medicines, as well as negative consequences.
In this brief review, only some part of studies is given as an example; pediatrics issues are almost not discussed.
However, the review clearly demonstrates that various methods of laser illumination (speciﬁc techniques are given)
make it possible to inﬂuence almost all the known pathogenesis of the disease, and low-level laser therapy is a truly
effective method of treatment.
We note that there are very few publications published on the topic outside of Russia. Russian scientists, as always,
are ahead of world science and low-level laser therapy practice.
Keywords: bronchial asthma, low-level laser therapy

B

ronchial asthma (BA) is one of the most
common diseases of the respiratory system in
children and adults. The life-long progression, the
high rate of aggravation and the often serious
condition at the height of an asthma attack, the
limited occupational aptitude and other characteristics increase the social signiﬁcance of the
disease. According to the latest epidemiological
studies, more than 339 million people in the
world suffer from BA [1]; 7.5% of the population
in the USA is afﬂicted with it, of which 1.8 million
people are hospitalized annually [2]. In Russia,
according to epidemiological studies, asthma affects about 7 million people (5e7% of adults and

10e15% of children) [3]. Many patients have
pronounced hormone dependence and/or various
hormone-related disorders. Reduced levels of
cortisol, testosterone, DHEA-s and estrogen in
patients with asthma below the normal range are
prognostic criteria for the deterioration of their
quality of life [4,5].
Regardless of the severity, BA is a chronic inﬂammatory disease of the respiratory passages
(RPs), occurring with the participation of mast cells,
eosinophils and T-lymphocytes, the release of a
large number of inﬂammatory mediators (Fig. 1).
Inﬂammation of the RPs causes their hyperreactivity, bronchial obstruction, and respiratory symptoms. With hyperactivity RPs narrow too easily and/

Received 12 July 2019; accepted 11 September 2019.
Available online 28 March 2020
* Corresponding author at: O.K. Skobelkin State Scientiﬁc Centre of Laser Medicine under the Federal Medical Biological Agency, Studencheskaya str., 40,
Moscow, 121165, Russia.
E-mail address: 7652612@mail.ru (S.V. Moskvin).
https://doi.org/10.37796/2211-8039.1000
0360-3199/Published by China Medical University 2020. © the Author(s). This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

REVIEW ARTICLE

Methods of effective low-level laser therapy in the
treatment of patients with bronchial asthma
(literature review)

2

S.V. MOSKVIN, A.A. KHADARTSEV
LOW-LEVEL LASER THERAPY

BioMedicine
2020;10:1e20

REVIEW ARTICLE
Fig. 1. Inﬂammation plays the central role in BA pathogenesis.

or strongly in response to the inﬂuence of provoking
factors. Bronchial obstruction is caused by the
following mechanisms: acute bronchospasm, edema
of the bronchial wall, obstruction by mucus and
remodeling of the bronchial wall. Recurrent exacerbations of asthma are based on inﬂammation of
the bronchi, their remodeling and impaired neurogenic control. An exacerbation of BA is associated
with increased inﬂammation of the RPs and can be
induced by a respiratory infection, exposure to allergens, or occupational sensitizing factors. Atopy,
the production of excess IgE in response to exposure
to exogenous allergens, is an important factor predisposing to the development of BA [3].
According to most experts, for successful treatment of patients with asthma, it is sufﬁcient to
properly divide patients according to the disease
severity and adjust drug dosages and prescribed
regimens for b2-agonists and systemic or inhaled
glucocorticosteroids (GCS) that have remained for
decades [2]. However, there has only been an increase in the number of patients throughout the
world, and so far not a single patient has really been
cured, i.e., no asthma attacks have been cured
permanently. The task is only to provide emergency
care [3]. The situation is complicated by the side
effects that all drugs have. Even the use of inhaled
corticosteroids comes with side effects, especially

when consuming high dosages. The resulting systemic absorption often leads to a blockade of the
hypothalamic-pituitary-adrenal system and the
development of complications such as glaucoma,
cataracts, osteoporosis and various skin lesions
[6e11].
The development of intoxication and hypoxia,
which impede the normal functioning of the immune system, is of great importance in BA pathogenesis. The effect of endotoxins on neutrophils is
determined by the severity of all bronchopulmonary
diseases, including bronchial asthma. The greatest
changes concern molecules of average weight,
circulating immune complexes (CIC), lipid peroxidation (LPO) and the toxicity index [12,13]. The
increased content of endotoxins in the blood of
asthma patients leads to a violation of the albuminbinding capacity and increased intoxication, as evidenced by a sharp increase in the albumin toxicity
index [12]. The involvement of histamine and serotonin in BA pathogenesis is generally recognized
[14]. The asthma exacerbation phase is characterized
by increased histamine and serotonin levels in the
blood and plasma, which is accompanied by the
development of an intense allergic reaction, reduced
phagocytic ability (both in phagocytic number and
phagocytic index) and an increased number of NBTpositive neutrophils [12].

A ramiﬁed chain of events plays a signiﬁcant role
in the pathogenesis of asthma, depending on the
functioning of almost all cellular elements of peripheral blood. The number of normal discocytes
decreases; the abnormal shapes of erythrocytes with
high cholesterol content on the membrane predominate; their deformability decreases, and their
aggregation ability increases [15,16]. The percentage
of abnormal shapes of erythrocytes (echinocytes,
teardrop-shaped and target cells, ovalocytes and
spherocytes) grows against the background of a
decrease in the number of discocytes and an increase in the total number of immature reticulocytes, resulting in the impaired oxygen
transport function of the blood and increased hypoxia [17].
According to our data, the main links of the
mechanism of therapeutic action in comprehensive
low-level laser therapy (LLLT) include the reduction
of side effects in the form of local or systemic reactions, the improvement in the indicators of
external respiratory function (ERF) and central hemodynamics, positive immune changes, the
improvement in adrenal cortex function and the
reduction in allergen-speciﬁc sensitivity and nonspeciﬁc hyperreactivity [18,19].
The therapeutic effect of low-intensity laser illumination (LILI) on BA, according to some authors,
begins with the response of immunocompetent
cells. The mechanism of formation of the cellular
response to laser screening ﬁnds its manifestation in
the initial phase of the development process, is
associated with changes in the activity of enzymes
and the structure of plasma membranes, and includes the following steps: molecular membrane
rearrangements e reducing cholesterol and fatty
acid saturation factor, increasing the proportion of
phospholipids and reducing microviscosity; functional modiﬁcation of membranes e changes in
lipid-protein interactions and increased transmembrane potential; and functional modiﬁcation of
cells e an increase in the phagocytic index and
neutrophil count [12,13].
As our studies have shown, exposure to LILI in
various modes allows for extremely effective increase in the deformability of erythrocyte membranes through their structural rearrangement. At
the same time, more than 90% of erythrocytes with
dysfunctional morphology restore their normal
discoid shape, which enables reduction of the level
of hypoxia [20].
The pathogenetic validity of various methods of
LLLT in the comprehensive treatment of patients
with asthma was conﬁrmed by numerous studies
[21e26]. Some national standards and clinical
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practice guidelines include almost all known
methods: exposure to LILI in the projection of the
thymus, adrenal glands, carotid sinus and Zakharyin-Ged zones, laser acupuncture, as well as intravenous laser blood illumination (ILBI) with red
(635 nm wavelength) spectrum, and extracorporeal
ultraviolet blood illumination (UVBI) [27,28].
Laser therapy should be considered as a multicomponent and pathogenetically substantiated
treatment of asthma patients, enabling the reversal
of the main symptoms of the disease more quickly
with an earlier cancellation or reduction of the drug
dosage. These measures contribute to the complete
recovery of electrophoregrams, rapid reduction of
the elevated sialic acid, seromucoid and ceruloplasmin level and enhanced kinin-kallikrein system
activity. After the LLLT course, a more pronounced
positive dynamics is observed in the external
respiration function (a decrease in the phenomena
of bronchial obstruction). In addition to a faster
onset and lengthening of remission periods, LLLT
allows the body resistance to colds and meteorological factors to increase [26].
The exposure to pulsed IR LILI also has an
immunomodulatory effect, along with a positive
clinical effect. The latter is manifested by increased
metabolic and mitotic activity of lymphocytes,
changes in the expression and afﬁnity of Elymphocyte receptors and the serum concentrations
of IgM. Neutrophil phagocytosis was signiﬁcantly
enhanced in the immune status of patients after the
treatment. From 1989 to 1994 15,526 patients with
various immunopathologies, including 2875 adults
and 12,651 children, were treated in several medical
clinics in Smolensk and Moscow (Russia) [29].
We do not signiﬁcantly address the topic of
treating asthma in children; it deserves a detailed
study in a special review, since treatment approaches differ signiﬁcantly. In this article we only
cite several publications from different Russian scientiﬁc schools as an example [30e41].
It should be noted that in the English-language
publications, and there are very few of them, only
laser acupuncture is used and only in the treatment
of children [42e49]. In Russia, laser acupuncture is
also in active use [50,51], however, most frequently
as part of the comprehensive treatment with the
adjustment of techniques [52], which is more logical
and effective.
A systematic review (search on Cochrane Library,
Medline, EMBASE, AMED, CINAHL, CNKI, VIP
electronic databases through February 2012), gives
13 randomized placebo-controlled trials (RCTs), the
results of which do not prove or disprove the
effectiveness of laser acupuncture for the treatment
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of bronchial asthma in children (the data are very
contradictory) [53]. However, this is not surprising,
since none of the publications describe the use of
optimal parameters of laser illumination for laser
acupuncture: 635 nm wavelength, power of
2e3 mW, exposure for 20e40 s per one corporal
point, and the maximum permissible values are
exceeded manifold, both in terms of laser power and
exposure time.
Experimental English-language publications are
also few in numbers [54e59], but they are extremely
important for understanding the mechanisms of the
biological action of LILI.
There are hundreds of times more studies and
publications of Russian scholars that not only prove
the highest efﬁciency of laser therapy, but also
substantiate the optimal parameters of laser illumination techniques, the principles of drawing up
optimal therapeutic schemes, based on many factors. There is nothing similar elsewhere in the
world.
Many experts believe that ILBI is the most universal and effective method of laser therapy for
asthma patients. The main advantage of ILBI is a
signiﬁcant reduction in the amount of medications
taken and a decrease in the number of asthma attacks after treatment [60e62], which is closely
related to the severity of the disease and the applied
option of the LLLT technique [63].
Table 1 presents the treatment outcomes for three
groups of patients after 10 daily laser therapy procedures for such daily average indicators (what fold
decrease was shown), as the frequency of asthma
attacks and the daily dose of b2-agonists. With regard to the GCS, the data is only qualitative: “signiﬁcant” dose reduction and the ability to make a
“soft” transition from systemic to inhaled medications [63; 64].
Group 1. Patients with mild and moderate-severe
atopic BA and allergic rhinitis were exposed to
continuous LILI (633 nm wavelength, power of
6 mW) endonasally for 5 min per each nasal
passage.

Table 1. Dynamics of reducing the frequency of asthma attacks (AA)
and the need for b2-agonists in patients with asthma depending on the
severity of the disease and laser therapy techniques [67].
Methods of Light
Medium
treatment/ AA b2-agonists AA b2-agonists
indicators

Strong

Group 1
Group 2
Group 3

e
1,5
2,5

4,2
3,6
e

2,3
3,5
e

2,5
4,2
2,0

2,5
1,7
1,4

AA b2-agonists
e
2,5
2,9

Group 2. Patients with mild, moderate-severe and
severe atopic and mixed BA were exposed percutaneously to pulsed IR LILI (890 nm wavelength,
power of 5 W, pulse repetition frequency of
150e3000 Hz): in the thoracic area, in the areas of
projection of the adrenal glands (the lumbar area at
the level of Th12 e L2), of the thymus (the sternum
area at the level of the second rib attachment) and
the vascular bundle (the left supraclavicular area).
Group 3. Patients with moderate-severe and severe
mixed and atopic BA were exposed to ILBI-635
(635 nm wavelength, power of 3 mW, 45 min
exposure time).
Patients demonstrated positive dynamics in the
course of the disease: the number of nocturnal
asthma and dyspnea symptoms was reduced, the
non-productive cough disappeared, and lung
auscultation was normalized. The clinical efﬁcacy of
LLLT was conﬁrmed by the ERF studies, and the
sputum leukocyte and eosinophil counts also
decreased in the patients [64].
Comparative evaluation of the clinical efﬁcacy of
LLLT in the comprehensive treatment of asthma
patients indicates the need for a differentiated use of
various methods depending on the form and
severity of the disease [63]. In our opinion, it is always better to apply combined and combinative
techniques.
Laser blood illumination (LBI) and most often its
intravenous option (ILBI) is the most common
method of laser therapy, which is used to treat BA
patients. The ﬁrst successful intravenous laser blood
illumination with continuous LILI of the red spectrum (633 nm wavelength, ILBI-635) was performed
in patients with bronchial asthma in the early 1980s,
that is, immediately after the technique had
appeared [65,66].
ILBI-635 is most effective in patients with the
atopic variant of bronchial asthma, who show no
effect from speciﬁc hyposensitization therapy. In
steroid-dependent patients, ILBI makes it possible
to reduce the dose of glucocorticosteroids or to
discontinue them at all, increasing sensitivity to
other medications. Laser therapy can be carried out
in any phase of the disease and as the prophylactic
treatment in BA patients who have sensitization to
plant pollen (prior to the pollination period). LLLT
has an immunomodulatory effect, adjusts the ratio
between the oxidant and antioxidant systems, and
normalizes the indicators of the respiratory function. The application of ILBI in the comprehensive
treatment of BA patients can reduce the number of
days of disability and lengthen remission periods by
2.4 times [66].

A hyperviscosity syndrome has been reported to
occur in BA patients: increased whole blood viscosity at low shear rates, reduced deformability and
suspension stability of erythrocytes, their increased
ability to hyperaggregate, echinocytosis, the tendency of platelets to slow and weakly reversible
aggregation [61]. Since the possibilities of exposure
to LILI that normalize blood rheology are well
known, S.A. Borzenkov (2000) [61] used ILBI-635
(wavelength 633 nm, power of 2 mW, 30 min
exposure time, 10 procedures per a treatment course
daily) in the comprehensive treatment of BA patients with positive clinical outcomes that correlated
with normalized rheological parameters. The minimum shear stress decreased by 14%, whole blood
viscosity reduced (at a shear rate of 1 cP - by 17%, at
a shear rate of 9 cP - by 12%, at a shear rate of 25 cP by 21%, at a shear rate of 100 cP - by 22%, and at a
shear rate of 256 cP - by 28%), single-unit RBC count
decreased by 47%, and the echinocyte count
reduced by 49% as well, the RBC deformability
increased by 1.2% and the non-aggregated RBC
count increased by 1.18%.
But at the same time, no effect on platelet aggregating properties was found in BA patients. The
application of ILBI in the comprehensive treatment
of asthma patients also enables decrease in the drug
dosage taken by more than 20% and reduction of
hospital lengths of patients’ stay on average by 2.91
days.
The use of ILBI-635 (633 nm wavelength,
1e1.5 mW, 30 min exposure time, 10 procedures per
a treatment course daily) to treat asthma enables to
obtain a more pronounced normalizing effect on
bronchial patency, reduce the degree of hypoxemia,
contribute to the improvement of the clinical picture
of the disease [17].
The synergistic effect of medication and laser
therapies on central hemodynamics, microcirculation and blood rheological properties makes it
possible to cancel prolonged b2-agonists and reduce
doses of systemic GCS [67], when prescribing ILBI
sessions, which is essential to compensate for the
negative effect of glucocorticoid therapy on the
morphofunctional state of endobronchial microhemocirculation [68].
ILBI-635 is known to have pronounced immunomodulatory properties associated with the effect of
illumination on the lymphoid elements of peripheral blood, which is also indicated for BA patients.
In addition, the content of physiologically active
substances, including glucocorticoid hormones, is
also changed in these patients. The level of total 11oxycorticosteroids (11-OCS) increases from (2e20)$
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105 g/l to (10e50)$105 g/l in the patients' serum
after ﬁve procedures of ILBI [69].
In patients with asthma in the acute phase, the
balance between LPO and the antioxidant system
(AOS) is disturbed, and the antioxidant activity of
blood signiﬁcantly decreases [12]. There is an
oxidative stress, which is expressed in signiﬁcant
(exceeding the average in healthy people by 12
times) hyperproduction of free-radical metabolites
against the background of 20% decreased activity of
intracellular antioxidant enzymes. The use of
inhaled GCS with the standard treatment of BA
patients leads to the positive dynamics of clinical
and functional parameters, but does not have an
appreciable impact on LPO and AOC parameters. In
standard therapy using systemic GCS patients show
a signiﬁcant decrease in LPO (by 33% of baseline
values) with simultaneous inhibition of AOC parameters (by 12% of baseline values). When
combining systemic and inhaled GCS, LPO parameters decrease less (by 25%), but the extent of
inhibition of AOS parameters is greater (a decrease
by 16%) [70]. Therefore, it is required to additionally
adjust LPO and AOS parameters against the background of GCS use in BA patients, at the same time
the ability of ILBI to normalize LPO processes is
well enough conﬁrmed [71].
The most signiﬁcant AOS disorders are observed
in hormone-dependent BA patients, but these patients show the best treatment outcomes after a
course of ILBI-635 (633 nm wavelength, power of
3 mW, 20 min exposure time, 8e10 procedures per a
treatment course daily). These results are correlated
with a signiﬁcant increase in the activity of antioxidant enzymes and a decrease in LPO intensity in
RBC. Against the background of ILBI, a decrease in
the average dosage of systemic GCS and a more
relaxed transition to inhaled drugs have been
observed. Patients who received ILBI against the
background of traditional therapy as opposed to
patients, who were traditionally treated, experienced faster clinical dynamics of the disease:
decrease in the number of asthma attacks, replacement of full-scale attacks of asphyxiation with
symptoms of dynamic bronchial obstruction, and
decrease in cough intensity. Against the background
of low-level laser therapy, there was a signiﬁcant
reduction in the need for bronchodilators and GCS
doses. The average bed-occupancy rate was 10.7%
less in such patients than in those who received only
traditional therapy. The most pronounced
improvement in respiratory function was observed
in the group of patients with newly developed
asthma [72e74].
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Research by V.I. Korzhov et al. (1989) [75] showed
that ILBI-635 in the comprehensive treatment of BA
patients enables to achieve remission in 92.1% of
cases and the phase of unstable remission in 7.9% of
cases (in the control group 73.8 and 26.2%, respectively). At the same time, in patients of the main
group (ILBI), the disappearance or decrease in the
number of asthma attacks occurred in 5e6 days,
while in the control group this result was achieved
in 8e10 days. A reliable decrease (by 15.8%) was
established in the concentration of molecules with
average weight as compared to the initial level, and
after treatment this parameter practically becomes
equal to that in healthy donors e 238 ± 10.5 units.
Analysis of the dynamics of accumulation of LPO
products revealed an increase in their level in the
studied patients; however, as a result of the treatment provided, the degree of normalization of both
intermediate and ﬁnal compounds is very signiﬁcant. Thus, the content of lipid hydroperoxides
decreased by 12.8% from the initial level, the
decrease in the concentration of malondialdehyde
(MDA) was even more signiﬁcant - by 34%.
An increase in the conjugated diene concentrations is registered in all patients with moderate-severe asthma during exacerbation of the disease.
These changes directly depend on asthma duration
[73,74,76]. Comprehensive treatment, including ILBI
procedures (633 nm wavelength, power of 2e3 mW,
20 min exposure time, 8e10 procedures per a
treatment course daily), to a greater extent contributes to reducing the intensity of LPO processes as
compared to traditional treatment.
The content of antioxidants in erythrocytes and
plasma increases in the exacerbation phase in BA
patients with short duration of the disease. In patients with the disease duration of more than 10
years against the background of an exacerbation, a
decrease is registered in the concentration of antioxidants in the studied media, respectively. The
application of ILBI-635 demonstrates a more pronounced tendency to normalize the studied parameters, i.e. this method is a powerful corrective
tool for affecting patients' AOS as well [77e79].
Other authors also conﬁrmed the best efﬁcacy of
laser therapy with disease duration of more than 10
years and a more severe course than with newly
diagnosed BA [80].
All BA patients have changes in the cytokine
proﬁle, cellular and humoral immunity, the nature
of which depends on the severity of the disease and
on the available allergic reactions. With an increase
in the severity of the disease, serum immunoglobulin (IgA) levels increase, while IgG and IgE
decrease, which is accompanied by an increase in
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the number of granulocytes with the phenotype
CD45 þ CD66b þ CD11bþ and enhanced phagocytic activity of neutrophils: the phagocytic number
increases by 3e16 times, and the phagocytic index
grows by 3.5e4 times as compared to healthy donors. Peripheral blood mononuclear cells isolated in
the exacerbation phase of bronchial asthma are
characterized by increased production of IL-4
(spontaneous production is 6.3 times as high,
induced one is 4.8 times as high), IL-6 (spontaneous
production is 2.4 times as high, induced one is 4.3
times as high) and IL-17 (spontaneous production
increases by 23%, induced one - by 19%). The level
of spontaneous production of IL-8 is reduced by 7%,
while that of the induced one is increased by 7.5%.
In this connection, recently, special importance has
been attached to immunomodulatory therapy [81].
Low-level laser therapy has also fairly powerful
capabilities in this component of the physiological
regulation.
It has been shown that in patients with an infectious-dependent form of BA ILBI-635 contributes to
the normalization of the number of E-rosetting cells,
a decrease in the content of theophylline-resistant
subpopulation of T-cells enhanced upon admission
and an increase in the number of theophyllinesensitive subpopulation of T-cells, which leads to
the normalization of theophylline-resistant-totheophylline-sensitive T-cell ratio: Eth-r-ROS/Eth-sROS [82]. After a course of ILBI-635, dyspnea is
reduced, the external respiratory function improves,
a more rapid recovery of alveolar blood ﬂow is
observed, a distinct stimulating effect on the cell
level parameters of phagocytic activity of neutrophils is reported [83,84].
It is most effective to administer ILBI-635 (633 nm
wavelength, 1e2 mW, 30 min exposure time, 5e7
procedures per a treatment course daily) for patients with moderate depression of the T-cell immunity. ILBI can be successfully used as
monotherapy in BA patients with mild disease and
drug polyallergy. The distinct positive dynamics in
the T-cell immunity naturally manifests itself in an
accelerated and pronounced regression of the clinical implications of the disease [85].
The inclusion of ILBI -635 in the comprehensive
therapy of infection-dependent BA increases the
effectiveness of treatment: it accelerates the time for
remission onset and increases its duration, reduces
the frequency of exacerbations and enables to
decrease the amount of drug therapy. Under the
inﬂuence of ILBI, the inﬂammatory process subsides, which is reﬂected in ERF improvement (VC
increases by 39.9%, FVC - by 27.9%, FEV1 - by
41.6%, MEF50 - by 42.0%, MEF75 - by 47.4%, MEF25

- by 58.3%), with marked fall in peripheral blood
eosinophils and positive general clinical dynamics
[86].
L.V. Vasilieva (1999) [87] showed the following
effects of ILBI-635 in bronchial asthma:
 stimulation of b-adrenergic receptors;
 increase in the functional activity of lymphocytes and
leukocytes, and phagocytic activity of neutrophils and
monocytes;
 normalization of immunoglobulin levels and CIC;
 restoration of the aggregative state of blood.

The use of intravenous laser blood illumination in
the comprehensive treatment of BA patients reliably
improves bronchial patency compared with the results of conventional therapy. ILBI-635 has a
corrective effect on the hemostatic system, mainly
optimizes Hageman-kallikrein-dependent ﬁbrinolysis, which determines an additional mechanism of
its action. In addition, ILBI has anti-aggregation
properties, reduces the coagulation potential, increases the antioxidant activity of the blood and
decreases pre-beta cholesterol and beta cholesterol
levels [88]. RBC morphometry and electrophoretic
mobility measurement in BA patients after ILBI
procedures show that the proportion of discocytes
in the blood recovers almost to the norm [89].
Many experts are sure that the combination of
plasmapheresis (PA) or enterosorption þ laser
blood illumination is one of the most effective options of therapy, including for BA patients
[28,60,62,90e93].
Plasmapheresis combined with ILBI-635 allows
for signiﬁcant (by 60%) improvement of performance in patients with the most severe clinical
course of asthma and concomitant autoimmune
thyroiditis. Comprehensive therapy not only contributes to obtaining stable long-term remission,
control over the BA symptoms, but also signiﬁcantly
reduces the antibody titer to the thyroid microsomal
fraction [90].
Against the background of comprehensive therapy applying PA, UVBI and ILBI, in most cases, it is
possible to achieve clinical remission in BA patients
with a pronounced reduction in the amount of drug
therapy, up to the discontinuation of hormonal
drugs. It was shown that the therapeutic effect of the
extracorporeal and laser therapy techniques is
implemented by enhancing the therapeutic efﬁcacy
of sympathomimetic agents [94], and increasing the
immunosorption and insulin-binding capacity of
erythrocyte membranes [94,95].
Combining drug therapy of BA patients with PA
and ILBI-635 it is possible to accelerate the onset of
the disease remission through more rapid reverse
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development of asthma attacks, which results in the
considerable increase in exercise tolerance and ERF
normalization. With a signiﬁcant reduction in the
volume of drugs, the periods of remission are
simultaneously extended. Combined treatment can
prevent the development of complications by
reducing the total doses of hormonal drugs or their
discontinuation. LLLT contributes to more rapid
stabilization of the bronchial receptor apparatus, in
particular of b-adrenoreceptors, increasing their
sensitivity to sympathomimetics and glucocorticoid
drugs. Combination of ILBI and PA to treat patients
with various forms of asthma corrects immune disorders and phagocytosis dysfunction, which is one
of the main pathogenetic mechanisms causing a
pronounced clinical effect and improving the course
of the disease [60].
These outcomes are conﬁrmed by other authors.
Against the background of PA and ILBI-635, cough
disappears in earlier periods and lung auscultation
is normalized, while the dose of oral GCS is
reduced, doubling the remission duration. After the
course of LLLT, respiratory indicators that characterize the bronchial patency are normalized by the
end of the 3rd week of treatment, providing rapid
functional activation of the oxygen-dependent
bactericidal system of blood neutrophils (NBT-test),
which is associated with an additional increase in
the T-lymphocyte suppressor potential, normalized
immunoregulatory index and increased phagocytic
activity of neutrophils [96e98].
According to A.S. Kuno (1994) [99], it is necessary
to include immunomodulators in the treatment
regimen in addition to PA and UVBI, which enable
to prolong remission by stabilizing humoral
immunity.
Along with ILBI, laser acupuncture is quite
actively used to treat BA patients; more often, as we
have noted above, as part of the comprehensive
therapy with other methods of low-level laser
therapy applied [52,93,100,101].
It was shown that the optimal time for local
exposure in treating patients with allergic BA by
pulsed IR LILI (890 nm wavelength, 5e7 W,
700e1600 Hz) is 60 s (paravertebrally), 300 s e
supraclavicular region, by illuminating APs for 30 s
(stimulation) and 60e90 s (suppression). The
following acupuncture points were used: V10
(Tianzhu), V11 (Dazhu), V13 (Feishu), V12 (Fengmen), V15 (Xinshu), V17 (Geshu), CV22 (Tiantu),
VC21 (Xuanji), VС20 (Huagai), VC17 (Shanchung).),
VC16 (Zhongting), VC15 (Jiuwei), RP6 (Sanyinjiao),
Е14 (Kufang), Е15 (Wuyi), Е36 (Zusanli), GI4 (Hegu),
Р7 (Lieque), P11 (Shaoshang). Auricular points:
AAP55 (Shen Men point, having general
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strengthening effect), AAP31 (Ping Chuan, Asthma
point, relieving symptoms of asthma, calming
panting, etc.), AAP13 (Adrenal Control point).
Against the background of combined laser therapy,
a positive ERF dynamics is observed, rhinocytogram
indices are normalized, there is reduction in general
and local eosinophilia), cutaneous and, especially,
local sensitivity to speciﬁc allergens. The positive
clinical effect of the therapy is accompanied by the
immune normalization: T-lymphocyte and T-helper
cell counts signiﬁcantly increase, the level of serum
immunoglobulins (IgA and IgG) raises, and the
percentage of degranulated mast cells decreases
[103].
Considerably worse results were obtained by
M.A. Borodina (1999) [104], either because of a
different acupuncture prescription, or because of
the multifactorial effect on APs (simultaneous
exposure to LILI, magnet and heat). An alternative
prescription is given by foreign authors: P5 (Chize),
Р7 (Lieque), P9 (Taiyuan), GI4 (Hegu), V13 (Feishu),
V23 (Shenshu), Е36 (Zusanli), RP6 (Sanyinjiao),
VG14 (Dazhui), VC17 (Shanchung). However, as is
often the case, they use completely unacceptable
LILI parameters [42], and perhaps for this reason
their results are not the best ones.
I.E Yesaulenko et al. (2009) [105] recommended a
simpliﬁed prescription to treat BA patients with
concomitant chronic rhinosinusitis: GI4 (Hegu), Р7
(Lieque), GI20 (Yingxiang) and Р5 (Chize), ZP15
(Jiabi), VG23 (Shangxing), АAР22 symmetrically on
alternate days, 10 procedures per a treatment course
daily.
Laser acupuncture can signiﬁcantly improve the
results of outpatient treatment and rehabilitation of
patients with light and moderate-severe asthma
statistically signiﬁcantly earlier than with conventional drug therapy.
Patients with severe BA demonstrate the best
result with comprehensive therapy. The clinical
course improves, bronchial sensitivity to sympathomimetics is restored, the need for b2-agonists,
inhaled and systemic GCS is reduced, Short-Term
Disability periods decrease by 5e7 days, remission
duration is prolonged to 3 years, there is reduction
in frequency of hospitalization by 1.3 times, emergency call incidence by 23%, and disability retirement rate to 12%.
The restoration of impaired histochematic barrier
and systemic changes in the synthesis and utilization of biogenic amines by the blood cells that
stimulate the production of mature heparin, which
binds inﬂammatory mediators e histamine and serotonin, as well as an excess of catecholamines is the
basic mechanism of therapeutic action of LILI.
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Heparin has anti-inﬂammatory value and removes
the blockade of b2-adrenergic receptors, and catecholamines produce bronchodilation, by binding to
b2-adrenergic receptors [51].
Summing up some intermediate result of the brief
review, we have systematized the results of various
studies (Table 2), which clearly demonstrate the
normalizing effect of laser illumination on virtually
all known pathogenetic mechanisms of asthma
development, therefore, there is no doubt that laser
therapy can and should be used as the basic method
of therapy. However, there is still a very important
issue about the optimization of laser therapy parameters; the answer to this question helps gain
knowledge of the mechanism of therapeutic action
of LILI and some rules. Sometimes it is hindered by
incorrect description of materials and research
methods [16], which raises doubts about the reliability of their results, but there are so many publications (Table 2 gives only a small part of them as
an example) that it is easy to draw conclusions about
the optimal techniques.
Laser blood illumination, as we said above, is the
most commonly used method for treating BA. While
the issue with the optimal power for the “classical”
ILBI-635 technique (633 nm wavelength) can be
considered solved (it should be 1e3 mW), the issue
with the exposure time is more complicated. Previously, laser illumination was performed by many
authors for 30 min or even more [17,61,85], although
it has long been unequivocally proven that the
exposure time for this mode of ILBI should not
exceed 15e20 min. Moreover, this conclusion was
made not only for bronchial asthma [76], but also for
other pathological processes and diseases [20].
It is known that in order to get the best treatment
outcome it is necessary to combine various methods
of LLLT for topical and systemic action [20], but this
is especially important if the patient has several
diseases.
Comparative evaluation of the clinical efﬁcacy of
laser therapy in the comprehensive treatment of BA
patients against the background of hormonal disorders conﬁrmed that precisely the combined
methods are most optimal when using laser illumination techniques of both primarily topical and
systemic action on the entire body as a whole [110;
122; 123]. Combining ILBI-635 and external LILI for
patients with various hormonal disorders characteristic of asthma improves the quality of patients'
life [5]. Long-term treatment of BA patients using
systemic GCS increases the risk of developing
osteoporosis. Low-level laser therapy (ILBI-635) is
an effective means of preventing complications and
helps normalize testosterone and estradiol levels

Indicator

LLLT technique (number of daily procedures)

Reference

Antioxidant System
ABA, children; reduction of bronchospasm attacks and
dyspnea, up to the complete disappearance
MBA; earlier normalization of the main clinical and
laboratory signs, reduction of the dose of GCS

Activation of AOS, reduction of the level of primary and final
LPO products
Reduction of MDA, lipid hydroperoxides, increase in SOD

ILBI-635 (3e5)

[106]

ILBI-635, external pulsed IR LILI: paravertebrally
Th3eTh5, at the II and III intercostal space,
symmetrically, projection of the adrenal
glands (14)
Enterosorption and ILBI -635 (10)

[87]

[62]

ILBI-635 (5e12)

[66]

660 nm, 30 mW, 5 min (1)

[55]

660 nm, 17,85 mW/cm2, 60 s (1)

[58]

Decrease in eosinophil count
Normalization of the ratio of T-and B-lymphocytes

Laser acupuncture (10e20)
ILBI-635 (3e5)

[107]
[106]

Reduction of general and local eosinophilia is accompanied by
normalization of immunity: the content of T-lymphocytes, Thelpers increases, the level of serum immunoglobulins A and G
increases, the percentage of degranulated mast cells decreases
Normalization of IgA, IgG and IgM levels
Normalization IgA, IgG, IgM, IgE levels, activation of
phagocytosis

Laser acupuncture (10e15)

[103]

LBI, laser acupuncture, in the projection (10)
PA and ILBI-635 (4e7)

[18]
[60]

PA and ILBI-635 (3e5)

[90]

633 nm (1)
Endonasal, topical, ILBI (10)
Laser acupuncture (10)
ILBI-635 (5e7)
Laser acupuncture (10)

[108]
[63,64]
[52]
[85]
[32]

ILBI-635 (5e8 on alternate days)
PA and ILBI-635 (8e10)

[82]
[96]

IABA; a signiﬁcant decrease in the amount of medications
taken and a reduction of the number of asthma attacks
ABA, IABA, MBA; reduction of doses of hormonal drugs
and cancellation, reduction of the days of disability,
lengthening the terms of remission 2.4 times
In vivo, mice

In vitro, U937 cells

Immune system
Not indicated
ABA, children; reduction of bronchospasm attacks and
dyspnea, up to the complete disappearance
IABA; decrease in skin and, especially, local sensitivity to
speciﬁc allergens

ABA
MBA; a signiﬁcant decrease in the amount of medications
taken and a reduction of the number of asthma attacks
after LLLT course
ABA, IABA with concomitant autoimmune thyroiditis;
increase in the duration of remission
In vitro
ABA, MBA; decrease in the frequency of attacks
ABA, children
MBA and COB; rapid regression of clinical symptoms
MBA, children; clinical symptoms are reduced 3e6 days
faster
IABA
IABA; remission occurs one week faster, its duration
increases; the severity of the disease decreases and the
frequency of exacerbations is reduced 2 times; the dose
of oral corticosteroids is reduced

Normalization of the work of AOS for all studied parameters
(DC, MDA, Schiff bases, SOD, catalase, glutathione peroxidase,
glutathione reductase)
Decrease in the content of LPO products (DC, MDA), increase in
enzyme activity (SOD, catalase), stabilization of cell membranes
Reduction of ROS content, decrease in activity of NO-synthase in
bronchoalveolar lavage fluid, increase in catalase activity, SOD,
glutathione peroxidase, NADPH oxidase, and Nrf2 transcription
factor
Suppression of glucocorticoid resistance induced by oxidative
stress, inhibition of TNF-a and IL-8 secretion through an increase
in cAMP and inhibition of the PI3K signaling pathway

Reduction of antibody titer to the microsomal fraction of the
thyroid gland
Changes in the morphofunctional state of lymphocyte membranes
Decrease in eosinophil count
Reduction of IgE level
Activation of T-cellular component of immune system
Reduction of IgE, VEGF, IL8, IL4 levels, CD4 þ lymphocytes,
increase in CD8 þ lymphocytes
Normalization of the ratio of Eth-r-ROS/Eth-s-ROS
Activation of neutrophils of peripheral blood
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Table 2. Pathogenetic justiﬁcation of the effectiveness of LLLT in patients with BA.
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Table 2 (continued )
LLLT technique (number of daily procedures)

Reference

Not indicated

Reduction of IgG, CIC levels, increase in phagocytosis and
normalization of the immunoregulatory index of the T-system of
immunity
Normalization of levels of immunoglobulins of the main classes
and reduction of the initially high level of IgE, normalization of
phagocytosis and levels of proinflammatory cytokines in blood
serum
Increase in metabolic and mitotic activity of lymphocytes,
neutrophil phagocytosis, changes in the expression and affinity of
E-receptors of lymphocytes, a decrease in IgM concentration in
blood serum
Normalization of IgA, IgG, IgM, IgE, IL-1b and TNF-a levels

PA and ILBI-635 (3e4)

[98]

External pulsed IR LILI (10)

[36]

External pulsed IR LILI (5e8)

[29]

External pulsed IR (890 mm) LILI (10)

[38]

Laser acupuncture (10e15)

[51]

ILBI-635 (5)
ILBI-635 (5e12)

[69]
[66]

633 nm, 20 mW
Externally on several areas by continuous
LILI of red spectrum (633 nm) and pulsed IR
(890 nm) LILI (7-10)
660 nm, 30 mW, 5 min (1)
660 nm, 30 mW, 5 min (1)

[13]
[41]

810 nm, 20 mW/cm2, 20 min (21)

[59]

650 nm, 31,25 mW/cm2, 42 and 300 s (1)

[54]

655 nm, 31,25 mW/cm2, 42 s and 5 min (1)

[56]

Initial low blood cortisol increases
The sensitivity of b-adrenoreceptors to sympathomimetics and
glucocorticoid drugs is increased

LBI, laser acupuncture, in the projection (10)
PA and ILBI-635 (4e7)

[18]
[60]

Increase in testosterone levels in men and estradiol in women

[4,5]

Increase in ACTH and cortisol levels in the blood

Pulsed IR LILI in the projection of the
adrenal glands and NLBI (10)
Hemosorption and ILBI-635 (8)

Normalization of aldosterone levels, increase in steroid hormones
levels in the blood

Pulsed IR in the projection of the upper
respiratory tract (10e15)

ABA, children; absence of severe asthma attacks and the
frequency of attacks of moderate and mild severity are
1.8e2.5 times less
ABA, adults and children

ABA, children; decrease in the number of asthma attacks 4
e6 times, reduction of the severity of the disease
ABA, HBA
Not indicated
ABA, IABA, MBA; normalization of sensitivity and
reactivity of the bronchi
Illumination of the blood of patients with MBA in vitro
Not indicated, children; the number of exacerbations
decreased 3 times, the need for antibiotics decreased 3.7
times
In vivo, mice
In vivo, mice

In vivo, rats

Muscle tone
In vivo, rats
In vivo, rats

Neuroendocrine system
ABA
MBA; a signiﬁcant decrease in the amount of medications
taken and a reduction of the number of asthma attacks
after LLLT course
MBA

Relaxation of the inflammatory smooth muscle of the trachea,
TNF-a inhibition, cAMP accumulation
Decrease in cholinergic hyperactivity, elimination of bronchial
smooth muscle spasm, reduction of the expression of mRNA
TNF-a

[55]
[57]

[91]
[6,109,110]
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Aspirin BA; 2 times lower doses of GCS and 2e2.5 times of
b2-agonists
Not indicated; reduction of GCS doses

Decrease in the number of eosinophils, normalization of IgA, IgG
and IgM levels
Normalization of T-cell immunity
Normalization of T-lymphocyte differentiation, increase in Tsuppressor activity, decrease in IgE production
Increase in phagocytic index and neutrophil count
Normalization of almost all investigated parameters of the
immune status (CD3 þ, CD4 þ, CD8 þ, CD16 þ, CD20 þ, IgA,
IgG, IgM)
Reduction of IgE level
Decrease in the number of eosinophils and bronchial
hyperactivity through the expression of the RhoA gene,
reduction of allergic lung inﬂammation through the
expression of the STAT6 gene
Decrease in the number of eosinophils, IL-4 and IgE levels,
increase in the production of IFN-g, the ratio of T-helpers
Th1/Th2 is normalized
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Not indicated

Not indicated
Vascular system, hemorheology
ABA, children; reduction of bronchospasm attacks and
dyspnea, up to the complete disappearance
Not indicated
Not indicated; a signiﬁcant decrease in the amount of
medications taken and a reduction of the number of
asthma attacks after LLLT course
ABA
MBA, children

MBA þ hypertensive disease
IABA; remission occurs one week faster, its duration
increases; the severity of the disease decreases and the
frequency of exacerbations is reduced 2 times; the dose
of oral GCS is reduced
Not indicated, combination with MS
IABA; improvement of bronchial patency

Not indicated
IABA

Laser acupuncture (10e15)

[51]

Laser acupuncture (15e20)

[111]

ILBI-635 (5)

[69]

Improvement of the structure of erythrocyte membranes

ILBI-635 (3e5)

[106]

Lengthening the blood clotting time, reduction of fibrinogen
concentration and increase in fibrinolytic activity of blood
Improvement of the rheological properties of blood, increase in
the deformability of erythrocyte membranes, decrease in the
content of echinocytes
Changes of indicators of central hemodynamics
Normalization of erythrocyte and platelet parameters, restoration
of endothelium-dependent characteristics (endothelin-1 and
circulating endotheliocytes)
Normalization of blood lipid spectrum
Improvement of central and peripheral hemodynamics

Laser acupuncture (10e20)

[112]

ILBI-635 (10)

[61]

LBI, laser acupuncture, in the projection (10)
Pulsed IR LILI in the projection of lungs (10)

[18]
[30,31]

ILBI-635 ()
PA and ILBI-635 (8e10)

[77]
[96]

Normalization of blood lipid spectrum
Hageman-kallikrein-dependent fibrinolysis is optimized, antiaggregation effect appears, coagulation potential decreases, blood
antioxidant activity increases, pre-beta cholesterol and beta
cholesterol levels decrease
Normalization of blood lipid spectrum
Restoration of the form of erythrocytes, an increase in the
proportion of discocytes in the blood
Increase in immunosorption and insulin binding ability of
erythrocyte membranes
Favorable effect on central hemodynamics, microcirculation and
rheological properties of blood
LLLT contributes to a more complete recovery of foregrams, a
rapid decrease in elevated levels of sialic acids, seromucoids,
ceruloplasmin, and the activity of the kinin-kallikrein system

ILBI-635 (8e10)
ILBI-635 (5)

[113e115]
[88]

Laser acupuncture (10e20)
ILBI-635 (10)

[116]
[89]

PA, UVBI and ILBI-635 (10)

[94]

ILBI-635 ()

[67]

Laser acupuncture, continuous LILI (633 nm)
on reflex zones (10e19 depending on the severity)

[26]

VC, FVC
VC, FVC, MEF25-75, FEV1, FEV1/FVC
VC, FVC, MEF25-75, FEV1, FEV1/FVC

Laser acupuncture (10e15)
LBI, laser acupuncture, in the projection (10)
ILBI-635, external pulsed IR LILI: paravertebrally
Th3eTh5, at the II and III intercostal space
symmetrically, the projection of the adrenal glands
(14)

[103]
[18]
[87]
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HBA, IABA; reduction in the amount of drug therapy up to
cancellation of hormonal drugs
ABA, IABA; broncholytic effect, cancellation of prolonged
b2-agonists and reduction of doses of systemic GCS
IABA; the main symptoms of the disease are stopped more
quickly with an earlier cancellation or reduction of the
dose of drugs
Respiratory function (normalization of indicators)
IABA
ABA
MBA; earlier normalization of the main clinical and
laboratory signs, reduction of the dose of glucocorticoids
taken

Initially reduced levels of cortisol and catecholamines in the
blood increase, initially increased levels of histamine and
serotonin are reduced
Increase in mineralcorticoid function of the adrenal cortex,
normalization of the ionic composition of blood (potassium,
sodium)
Increase in levels of 11-oxycorticosteroids (11-OCS) in the blood
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ABA, HBA
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Table 2 (continued )
Indicator

LLLT technique (number of daily procedures)

Reference

MBA

FVC, FEV1, FEV1/FVC

[4]

ABA, children
ABA; elimination of bronchospasm
MBA, children
ABA, MBA; decrease in the frequency of attacks
MBA and COB; rapid regression of clinical symptoms
MBA, children; clinical symptoms are reduced 3e6 days
faster
ABA, children; absence of severe asthma attacks and the
frequency of attacks of moderate and mild severity are
1.8e2.5 times less
BA and hypertensive disease
MBA
ABA, IABA, MBA
ABA, IABA, MBA; elimination of bronchial obstruction
syndrome
ABA, HBA; the need for b2-agonists, inhalation and
systemic GCS decreases, the period of temporary
disability decreases by 5e7 days, the duration of
remission increases up to 3 years
ABA, children; absence of severe asthma attacks and
reduction of the frequency of attacks of moderate and
mild severity
IABA
MBA; improvement of bronchial patency of large, medium
and small bronchi due to a pronounced antiinﬂammatory, bronchodilator, anti-edematous,
antioxidant action
MBA with rhinosinusitis
Not indicated, children; improvement according to GINA
criteria in 91.7% of patients, reduction of doses of
medications
Not indicated, children
Not indicated, children
Not indicated, children
Not indicated, children
Not indicated, children; improvement of the quality of life

PEF, FEV1
VC, FVC, FEV1, FEV1/FVC, PEF, etc.
FVC, PEF
VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF
VC, FVC, MEF25-75, FEV1, FEV1/FVC
VC, FVC, MEF25-75, FEV1, FEV1/FVC

Pulsed IR LILI in the projection of the adrenal
glands and NLBI (10)
Laser acupuncture (10)
Laser acupuncture (10e20)
Pulsed IR LILI in the projection of lungs (10)
Endonasal, topical, ILBI (10)
ILBI-635 (5e7)
Laser acupuncture (10)

[52]
[100]
[30,31]
[63]
[85]
[32]

VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF

External pulsed IR LILI (10)

[36]

MEF75, FEV1, PEF25-75, normalization of blood pressure
FEV1, PEF, reduction of endogenous intoxication
VC, FVC, MEF25-75, FEV1, FEV1/FVC
VC, FVC, FEV1, FEV1/FVC, PEF

External, NLBI (10)
NLBI, laser acupuncture (12e14)
NLBI, ILBI-635 (8)
ILBI-635 (5e12)

[117]
[118]
[80]
[66]

VC, FVC, FEV1, MEF50,75

Laser acupuncture (10e15)

[50,51]

VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF

External pulsed IR LILI (10)

[40]

VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF
VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF

ILBI-635 (5)
NLBI (10)

[86]
[119,120]

VC, FVC, MEF25-75, FEV1, FEV1/FVC, PEF
VC, FEV1, FEV1/FVC

Pulsed IR LILI endonasally
Laser acupuncture (10)

[121]
[42]

VC, FEV1, FEV1/FVC, PEF
FEV1, MEF25
PEF
VC, FVC, MEF25-75, FEV1
PEF, FEV1

Laser
Laser
Laser
Laser
Laser

[43]
[44]
[46]
[48]
[49]

acupuncture
acupuncture
acupuncture
acupuncture
acupuncture

(10)
(10)
(10)
(10)
(10)
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Notes: ABA e atopic BA; BA e bronchial asthma; COB e chronic obstructive bronchitis; ILBI - intravenous laser blood illumination; HBA e hormone dependent BA; GCS e glucocorticosteroids; DC e diene conjugates; VC e vital capacity; IABA e infectious-allergic BA; IFN e interferon; LLLT - low-level laser therapy; MDA e malondialdehyde; MEF25-75 e
maximal expiratory ﬂow at 25%e75%; MS e metabolic syndrome; NLBI- non-invasive (percutaneous) laser blood illumination; FEV1 e forced expiratory volume in 1 s; FEV1/FVC e
the Tiffeneau index; PA e plasmapheresis; LPO e lipid peroxidation; PEF e peak expiratory ﬂow rate; MBA e mixed BA; SOD e superoxide dismutase; FVC e forced vital capacity;
cAMP e cyclic adenosine monophosphate; CIC e circulating immune complexes; GINA e Global Initiative for Asthma; IL e interleukin; NF-kB e nuclear factor-kappa B; NO e
nitrogen oxide; PI3K e phosphoinositide 3-kinase; TNF-a e tumor necrosis factor-alpha; VEGF e vascular endothelial growth factor.
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[124]. Combining ILBI-635 and external LILI is most
effective for osteoporosis prevention in patients
taking GCS [44].
The availability of BA determines the peculiarities
of hypertension progression, since a sharp rise in
blood pressure often occurs at the time of a suffocation attack or an increase in bronchial obstruction,
leading to negative consequences. Laser therapy in
this case acts as a non-speciﬁc therapeutic factor,
providing a pronounced double effect, promoting
the improvement of the bronchial patency of the
large, medium and small bronchi due to a pronounced anti-inﬂammatory, bronchodilatory, antiedematous, antioxidant action, simultaneously
normalizing blood pressure and preventing its
sharp jumps [117,119,120].
The efﬁcacy of combined LLLT for patients with
asthma and stage 1 hypertensive disease is 80%, and
for patients with asthma and stage 2 hypertensive
disease is 70%, respectively. It is recommended to
expose consistently the projection of the vasomotor
center of the brain e the region of the posterior
cranial fossa (1 min, 800e1500 Hz frequency), the
projection of kidneys (for 5 min per each,
80e1500 Hz frequency), the projection of the lower
lung lobes symmetrically (2 min, 80 Hz frequency)
with pulsed IR LILI (904 nm wavelength, 100 ns light
pulse duration, 8e10 W) paravertebrally at the
C4eC6 level, at the Th2eTh6 level (for 1 min per
each, 80e150 Hz), 10 procedures per a treatment
course daily [117].
A special situation develops in BA patients with
hormonal disorders and metabolic syndrome (MS).
In case of bronchial disorders accompanied by
bronchial obstruction, the leading role in the genesis
of the impaired functional status of the adrenal
glands is assigned to chronic hypoxia and hypoxemia (as a result of impaired bronchial patency and
alveolar hypoventilation), which are the trigger
mechanisms of stress. Rapid response activation of
the hypothalamic-pituitary-adrenal system causes a
standard non-speciﬁc reaction in the form of adrenocortical hypertrophy, lymph node atrophy, etc. In
the conditions of pathology, the adaptive role of a
number of hormones consists primarily in their inﬂuence on the development of inﬂammatory processes. The possibility of correcting the
neuroendocrine system work after laser therapy is
conﬁrmed by the normalized serum aldosterone
levels in such patients [6].
There are common key links in the pathogenesis
of BA and MS: energy dependence of these processes, increased consumption of plastic material
with involvement of the immune system in pathological reactions, activation of cytokine mechanisms,
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intense work of the endocrine system with active
release of hormones and neurotransmitters into the
blood. With this in mind, it can be assumed that a
proper correction of MS contributes to the development of positive dynamics for the bronchial
asthma progression. Laser therapy methods allow
obtaining good treatment outcomes and are an
effective means of preventing the development of
complications [113e115]. The developed method of
combined therapy for BA patients can increase the
treatment efﬁcacy and shorten the treatment duration, prevent side effects, correct hormone levels
and reduce the dose of drugs used. Against the
background of drug therapy, patients are exposed to
NLBI and pulsed IR LILI in the projection of the
adrenal glands. In this case, the NLBI is performed
for 15 min at a wavelength of 635 nm. Before the 1st
and 5th procedures of exposure to the pulsed IR
LILI, the levels of cortisol and estradiol in women
and testosterone in men are determined. At cortisol
levels below 230 nmol/l and testosterone levels
below 500 ng/dl in men and estradiol levels below
30 pg/ml in non-menopausal women and below
15 pg/ml in menopausal women, a pulse repetition
frequency of 150 Hz is used. At the cortisol levels
ranging from 230 to 750 nmol/l and estradiol levels
ranging from 30 pg/ml to 160 pg/ml in women and
testosterone ranging from 260 to 1593 ng/dl in men,
a pulse repetition frequency of 80 Hz is used. The
total time of the procedure is no more than 18 min.
The treatment course consists of 10e12 daily procedures [125].
External illumination by pulsed IR LILI is carried
out in BA patients either in the projection of the
upper respiratory tract to stimulate b-adrenergic
receptors, eliminate inﬂammation and bronchospasm, or in the projection of the adrenal cortex to
stimulate the release of steroid hormones
[26,109,110,114]. Most often, both variants are used
with the aim of simultaneously affecting several
mechanisms of the disease pathogenesis.
The possibility of using reﬂex zones in treating
patients with allergic asthma for stimulation of
blood circulation and trophism is noted. In this case
laser illumination is performed paravertebrally in
the C7eTh6 area in addition to exposing the projection of the inﬂammatory inﬁltrate and the adrenal
cortex. When using this technique, persistent
remission (no recurrence within 2e3 years) was
observed in 14% of patients (with mild progression
of the disease), who simultaneously stopped taking
GCS. Relative remission, characterized by the
absence of full-scale asphyxiation attacks during
1.5e2 years and occasional difﬁculties in breathing,
occurred in 65% of patients [26].
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We have shown the need to control the hormone
content in the process of laser therapy of BA patients. A
method of exposure was proposed, consisting in illuminating two paravertebral and intercostal regions
and two Krenig ﬁelds by pulsed IR LILI (890 nm
wavelength,
8e10
W/cm2
power
density,
1500e3000 Hz frequency, 5 min exposure time, 10
procedures per a treatment course daily). This technique is characterized by the use of additional modulation
in
the
well-known
“BIO”
mode
(synchronization of changes in the LILI power with
patient's pulse and respiration frequency). In addition,
after the 1st and 3rd LLLT procedures, the content of
11-oxicorticosteroids (11-OCS) is determined; in case
of a decrease in their content further treatment continues. In the majority of patients (80%) with a good
and satisfactory effect of LLLT, there was a signiﬁcant
decrease in the level of 11-OCS in the blood plasma
and daily urine after the 1st procedure, and this trend
continued until the end of the treatment. In patients
with an unsatisfactory treatment outcome, the level of
11-ACS either did not change or tended to increase.
The mode of illumination (power, frequency) was
modiﬁed in a number of patients based on the change
in the level of 11-OCS after the ﬁrst procedure. In some
cases, the dynamics of 11-OCS in the absence of a
pronounced clinical effect suggested the indirect effect
of LILI on metabolic processes in the lungs, which was
conﬁrmed later on by signiﬁcantly better curability of
patients when using drug therapy [126].
When treating BA patients with metabolic syndrome, Kryuchkova et al. (2011) [127] recommended
combining ILBI with external exposure to green
light. Although in our opinion, this is hardly more
effective than pulsed infrared LILI, even if we
consider the situation only in terms of the depth of
penetration, not to mention the special “healing
properties” of coherence [128]. Light in the green
region of the spectrum, regardless of the monochromaticity degree, is almost completely absorbed
already in the upper layers of the skin, penetrating
no more than a few millimeters, and therefore, it
cannot directly affect the bronchi [20]. Although the
issues of implementing the reﬂex mechanism and
psychotherapeutic effects may well be discussed.
Endobronchial technique, which was used by
some experts [129,130], did not ﬁnd practical application due to the complexity of implementation with
the worst treatment outcomes, which are achieved
by using other methods of laser illumination.
Summing up the literature review, knowing the
disorders that underlie the pathogenesis of the disease (Fig. 1), as well as the biomodulating mechanisms of the LLLT, we have drawn a scheme (Fig. 2)
that clearly illustrates the basic mechanisms
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underlying the treatment of patients with bronchial
asthma.
It seems promising to use low-intensity illumination of the extremely high-frequency range and
laser light (EHF-laser therapy) [131], some progress
has already been achieved in this direction [132,133],
but the optimization of exposure parameters is
clearly required.
Proceeding from the above data and an understanding of the methodology as a whole, we present
laser therapy techniques with optimal parameters
that are recommended for the treatment of patients
with various forms of bronchial asthma, once again
emphasizing the need for combination and
variation.
ILBI-635 Technique: Matrix and Lasmik laser
therapeutic devices, KL-ILBI-635-2 laser emitting
head (635 nm wavelength, light guide output power
of 1.5e2.5 mW, 15e20 min exposure time), 5e10
procedures per a treatment course daily [83,87].
Based on the well-known fact that the LLLT efﬁcacy
is observed with a disease duration exceeding 10
years and a more severe course than with newly
diagnosed BA, it is recommended to reduce the
exposure time for this category of patients down to
3e5 min for ILBI-635 [80].
It is also required to reduce the exposure time
down to at least 7e10 min in all children (5e7 procedures per a treatment course daily) [106].
Although, in our opinion, in pediatrics, it is preferable to use a non-invasive option of the laser blood
illumination technique e in the projection of the
supraclavicular region on the left (the technique
parameters depend on age).
For the last 8e10 years such “classic” version of
ILBI has been actively supplanted by a more effective combined technique, which allows both inﬂuencing the immune system and activating
metabolism. It is highly recommended to combine
laser blood illumination with plasmapheresis.
ILBI-635 þ LUVBI® Technique: Matrix and Lasmik laser therapeutic devices, KL-ILBI-635-2 laser
emitting head (red spectrum, 635 nm wavelength,
light guide output power of 1.5e2 mW, 10e20 min
exposure time) and KL-ILBI-365-2 laser emitting
head 365e405 nm wavelength, light guide output
power of 1.5e2 mW, 3e5 min exposure time). It is
recommended to perform 10e12 procedures per a
treatment course daily with mode alternation in a
day [20].
ILBI-525 þ LUVBI® Technique: Matrix and Lasmik laser therapeutic devices, KL-ILBI-525-2 laser
emitting head (green spectrum, 525 nm wavelength,
light guide output power of 1.5e2 mW, 7e10 min
exposure time) and KL-ILBI-365-2 laser emitting
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Fig. 2. Low-level laser therapy mechanisms in the treatment of BA patients.

head 365e405 nm wavelength, light guide output
power of 1.5e2 mW, 3e5 min exposure time). It is
recommended to perform 10e12 procedures per a
treatment course daily with mode alternation in a
day [20]. The most advanced version of ILBI, which
has proven its effectiveness in many diseases;
however, it is necessary to conduct appropriate
clinical studies and test the applicability in bronchial
asthma.
According to S.V. Papkov (2002) [80], regardless of
the LLLT technique used, in the overwhelming majority of cases, the course treatment of BA patients
should be limited to 8 procedures daily for 10e15 min,
since longer exposure has a stressful effect, leading to
worsening of some autonomic parameters of the
body. From this viewpoint, ILBI-525 þ LUVBI®
technique is also preferable to ILBI-635.
Non-invasive laser blood illumination (NLBI): The
technique is not applied on the same day as ILBI.
Wavelength of 635 nm, pulsed mode, ML-635-40
matrix laser emitting head (Matrix or Lasmik device,
eight 4e5 W laser diodes), power of 50e80 W, power
density of 4e5 W/cm2, frequency of 80 Hz (variation
is not allowed).
Laser acupuncture: Wavelength of 635 nm,
continuous or modulated operation mode, and the
output power at a special acupuncture nozzle is
2e3 mW, to be exposed for 20e40 s on one corporal

point, the prescription is selected individually or on
the recommendation of specialists.
In the projection of the internal organs Wavelength of 904 nm, pulsed mode, ML-904-80 matrix
laser emitting head (Matrix or Lasmik device, eight
10 W laser diodes), power of 50e80 W, power density of 8e10 W/cm2, frequency of 80 Hz (variation is
allowed).
Localization (projection) and exposure time:
 upper respiratory tract - 2 or 5 min, 1e2 areas;
 thymus - 1 min;
 adrenal cortex - 2 or 5 min per area symmetrically.

Paravertebrally: Wavelength of 904 nm, pulsed
mode, LO-904-20 matrix laser emitting head with a
mirror expender (Matrix or Lasmik device, one laser
diode), power of 15e20 W, power density of
10e15 W/cm2, frequency of 80 Hz (variation is not
allowed) at the level of C4eC6 and Th2eTh6 symmetrically, 1 min per each region.
Endonasal technique: The application of the
technique is associated with the execution of certain
mandatory rules. Continuous LILI of the red spectrum (635 nm wavelength, light guide output power
of 3e5 mW) through the light guide or directly via
the laser emitting head to expose for 2 min per one
nasal passage. The efﬁcacy and validity of the
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technique is beyond doubt [64; 134]; however, it is
necessary to carefully consider its purpose, to control the technique parameters, especially the exposure time.
In case of bronchial asthma with concomitant
chronic rhinosinusitis, another technique is used,
although the nasal area is exposed. Firstly, only
pulsed IR LILI (890e904 nm, 5e10 W, 80 Hz) should
be used, secondly, there is other localization: projections of maxillary sinuses and/or frontal sinuses
and/or ethmoidal sinuses (depending on the localization of the inﬂammatory process according to xray or computed tomography data) on both sides,
for 2 min each [121].
Most often, 10e15 daily procedures are recommended per a treatment course. Although there are
other options, both upwards and downwards, we
agree precisely with this approach. Fewer procedures will not allow obtaining a stable clinical effect,
and more does not make sense according to the
logic of the known patterns of chronobiology and
chronomedicine.
The issue of alternating different techniques is
also very important. In our opinion, if guided by the
well-known rule of limiting the total procedure time
to 20e25 min, then on one day 2-3-4 different options
of laser illumination may and should be performed.
The opinion of some experts that it is optimal to
combine ILBI-635 with the exposure to pulsed IR
LILI in the projection of the trachea region (supradorsal) and paravertebral every other day, 10e12
procedures per a treatment course daily [122], is
most likely related to the wrong exposure time
selected for ILBI.
Thus, low level laser therapy for BA patients with
proper prescription and appropriate procedures,
results in sustained remission throughout the patient's entire life. Moreover, drugs are not excluded
from the treatment regimen, but are considered as
part of the auxiliary treatment to provide emergency
care in case of unforeseen and/or provoked exacerbation. Courses of prophylactic laser therapy are
recommended: 3e5 procedures daily or every other
day, at least 3e4 times a year [26,36,60,82,85,86]. It is
preferable to use two techniques, most often ILBI
and topical exposure. A course of prophylactic
treatment is additionally prescribed for patients
with allergic BA before the onset of seasonal
exacerbation.
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